Johnson & Johnson announced positive three-year data from its Phase 3 GALAXI 2 and 3 trials for TREMFYA in Crohn's disease, demonstrating durable efficacy and a consistent safety profile. This reinforces the drug's potential in a significant market, offering a long-term treatment option for patients and strengthening J&J's pharmaceutical pipeline.
Johnson & Johnson released three-year data from its Phase 3 GALAXI 2 and 3 trials for TREMFYA (guselkumab) in moderately to severely active Crohn's disease. The data, to be presented at ACG 2026, showed durable efficacy and a consistent safety profile over 144 weeks. This is significant because it validates TREMFYA's long-term potential as a treatment for a chronic condition, which can lead to increased market share and revenue for J&J. For traders, this represents a positive long-term development for JNJ's pharmaceutical segment, potentially boosting investor confidence in its pipeline and future growth prospects, though the immediate market impact might be moderate as this is an extension of previously known positive results.